IRADIMED CORP — Director's Dealing 2019

Sep 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IRADIMED CORP (IRMD)
CIK: 0001325618
Period of Report: 2019-09-13

Reporting Person: JOHNSON BRENT (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-09-13	Common Stock	A	3000	$0.93	Acquired	4368	Direct
2019-09-13	Common Stock	S	3000	$21.42	Disposed	1368	Direct
2019-09-16	Common Stock	A	3000	$0.93	Acquired	4368	Direct
2019-09-16	Common Stock	S	3000	$21.89	Disposed	1368	Direct
2019-09-17	Common Stock	A	2000	$0.93	Acquired	3368	Direct
2019-09-17	Common Stock	S	2000	$22.88	Disposed	1368	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-09-13	Stock Option (Right to Buy)	$0.93	M	3000	Disposed	2021-12-27	Common Stock (3000)	Direct
2019-09-16	Stock Option (Right to Buy)	$0.93	M	3000	Disposed	2021-12-27	Common Stock (3000)	Direct
2019-09-17	Stock Option (Right to Buy)	$0.93	M	2000	Disposed	2021-12-27	Common Stock (2000)	Direct

Footnotes

F1: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019.

F2: This transaction was executed in multiple trades at prices ranging from $20.25 to $22.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $21.15 to $22.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $22.74 to $23.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.